Galanin NAX 810-2 - Galanin Receptor-2 Based Therapy

PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
PRE
P1
P2
P3
Edit

Updated: 08/27/2019

Pipeline Type

New Drugs in Development

Phase Of Development

Preclinical

Sponsors and Collaborators

University of Utah; NeuroAdjuvants, Inc., Epilepsy Foundation (EF), Milken Family Foundation

Mechanism of Action

Other

Mechanism Description

Activates galanin receptor subtype 2

Populations Tested In

N/A

Other Resources

Special FDA Designation

Nonprofit or Government Support

Nonprofit

Nonprofit or Government Support Description

Epilepsy Foundation - NTCG 2006

Previous Presentations

Presented at meetings (latest date) (Pipeline, AEDD; AES, Eilat, etc)
N/A

Location of Clinical Trials

N/A

Clinical Trial link

Sign Up for Emails

Stay up to date with the latest epilepsy news, stories from the community, and more.